94%Confidence
0Views
FDASource
2026-03-02Date
Summary
Asteria Health's estradiol pellet recall expands the contamination issue beyond testosterone products, indicating possible facility-wide particulate contamination problems. This broad quality failure suggests inadequate environmental controls affecting their entire sterile pellet manufacturing process.
Actionable: Assume Asteria Health's entire product line may be compromised and consider alternative suppliers for hormone replacement therapies.
AI Confidence: 94%
Data Points
firmF.H. INVESTMENTS, Inc. (dba Asteria Health)
classificationClass II
statusOngoing
distributionNationwide in the USA
productESTRADIOL, 25 mg, 1 Sterile Pellet, Asteria Health 432 Industrial Ln, Birmingham, AL 35211, NDC: 79559-3025-32.
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now